{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-044766","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2024-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.004372+00:00","generated_at":"2026-06-04T01:21:39.981735+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Mallinckrodt plc dismisses Deloitte as auditor, appoints PwC","bullets":["Dismissed Deloitte & Touche effective April 3, 2024; engaged PricewaterhouseCoopers for FY ending Dec 27, 2024.","No disagreements with Deloitte of the type under Item 304(a)(1)(iv) during audit periods or through April 3, 2024.","No reportable events under Item 304(a)(1)(v) occurred during same periods.","Deloitte's audit reports on prior financials contained no adverse opinion or qualification."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-044766","json":"https://secwatch.observer/filing/0001104659-24-044766.json","markdown":"https://secwatch.observer/filing/0001104659-24-044766.md","text":"https://secwatch.observer/filing/0001104659-24-044766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000110465924044766/0001104659-24-044766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000110465924044766/tm2411283d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:21:39.981735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03b463b8c7ca5106ceb425a3bd3f658952c9e1c1","claim":"Keenova Therapeutics plc dismissed Deloitte & Touche LLP as its auditor.","evidence_excerpt":"result of this process, on April 3, 2024, upon the recommendation of the Audit Committee, the Board approved the dismissal of Deloitte & Touche LLP (“ Deloitte ”) as the Company’s independent registered public accounting firm, effective immediately.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465924044766/0001104659-24-044766-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Deloitte & Touche LLP"},{"label":"Successor","value":"PricewaterhouseCoopers LLP"}],"fact_type":"auditor_change"},{"claim_id":"57443f622029c002dac49ab6751a04bb17569819","claim":"Keenova Therapeutics plc engaged PricewaterhouseCoopers LLP as its auditor.","evidence_excerpt":"Also, on April 3, 2024, the Audit Committee approved the engagement of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 27, 2024, effective immediately.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465924044766/0001104659-24-044766-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"PricewaterhouseCoopers LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}